EyeCon 2026 Banner
|Articles|January 12, 2021

Clearside Biomedical's axitinib injectable suspension phase 1/2a trial enrolls first patients

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.


Latest CME